Latest news with #OlinkExploreHT
Malaysian Reserve
27-06-2025
- Business
- Malaysian Reserve
Ultima Genomics Selected to Support the World's Largest Proteomics Studies to Date Led by Regeneron Genetics Center
FREMONT, Calif., June 26, 2025 /PRNewswire/ — Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that its UG 100 ™ sequencing platform has been selected to support Regeneron Genetics Center® (RGC™) and its recently launched U.S. large-scale proteomics study. The study, comprised of 200,000 blood serum samples secured by RGC from its long-standing research collaboration with Geisinger Health System, will be combined with the recently announced UK Biobank Pharma Proteomics Project, the largest proteomics study undertaken to date, which will also utilize Ultima's UG 100 sequencing platform for the analysis of 600,000 samples from UK consented participants. Combined, these studies reflect the growing role of high-throughput, cost-efficient sequencing in enabling large-scale counting applications across proteomics and other emerging omics fields. For these efforts, RGC will utilize the Olink Explore HT platform and Ultima's UG 100 platform. Ultima's technology was selected for its scalability, efficiency, and suitability for large population-level studies requiring high-throughput data generation. 'We are pleased to continue supporting the ever-expanding large-scale proteomics studies that have the potential to drive important scientific and clinical insights,' said Gilad Almogy, founder and CEO of Ultima Genomics. 'These RGC proteomics studies build on the growing momentum we are seeing for population-scale proteomics and counting applications powered by Ultima's sequencing platform.' About Ultima Genomics Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit Ultima Media ContactVikki Herrera408-206-7009vikki@
Associated Press
12-06-2025
- Business
- Associated Press
Regeneron Genetics Center Selects Olink® Explore HT for Landmark Proteomics Study of 200,000 Patient Samples
UPPSALA, Sweden--(BUSINESS WIRE)--Jun 12, 2025-- Thermo Fisher Scientific, the world leader in serving science, today announced that the Regeneron Genetics Center ® (RGC™) has selected the Olink Explore HT proteomics platform for a large-scale proteomics investigation involving nearly 200,000 patient samples from the Geisinger Health Study that aims to unlock new insights into the dynamic biology and mechanisms of human disease. The Geisinger Health Study, characterized by deep phenotyping data, offers a unique opportunity to monitor proteomic changes at scale. RGC's established infrastructure is designed to manage large-scale projects and is built for the efficient execution of this ambitious endeavor. RGC's selection of Olink Explore HT follows the platform's selection for use in the UK Biobank Pharma Proteomics Project (UKB-PPP), the world's largest human proteomics study. The Geisinger Health Study aims to validate genetic hypotheses, solidify drug targets identified by RGC's world-class genomic sequencing operation, and discover novel disease biomarkers to improve drug development efficiencies. Olink Explore HT was chosen for its unparalleled scalability, high throughput, and superior specificity, all of which are essential for processing such a vast number of samples. 'We are thrilled to partner with RGC on this groundbreaking project,' said Carl Raimond, president, proteomic sciences, Thermo Fisher Scientific. 'The selection of Olink Explore HT underscores its ability to deliver robust and reliable data at scale. This important work will accelerate the pace of biomarker discovery and contribute significantly to the advancement of precision medicine.' RGC is a cutting-edge research organization focused on uncovering genetic and proteomic insights, ensuring superb data stewardship, and ultimately driving scientific advancements in preventing and treating human disease. The integration of Olink Explore HT into their workflow signifies another major step forward in their commitment to leveraging multi-omics data for improved outcomes. 'The Olink Explore HT platform has proven to be an invaluable tool in our pursuit of deeper biological understanding,' stated John Overton, Vice President at Regeneron Genetics Center. 'Its scalability and specificity are essential for handling the complexities of a project of this size. We believe this ambitious endeavor will yield transformative insights that will drive innovation in scientific discoveries.' The comprehensive mapping of protein levels across such a large population of patient samples represents a significant milestone in the field of proteomics, paving the way for future studies to advance our understanding of human health and disease. Learn more about Olink Explore HT . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit . View source version on CONTACT: Media Contact: Michael B. Gonzales, PhD Thermo Fisher Scientific E-mail:[email protected] KEYWORD: EUROPE SWEDEN UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH GENETICS HEALTH TECHNOLOGY CLINICAL TRIALS RESEARCH SCIENCE SOURCE: Thermo Fisher Copyright Business Wire 2025. PUB: 06/12/2025 08:15 AM/DISC: 06/12/2025 08:16 AM
Yahoo
12-06-2025
- Health
- Yahoo
Regeneron Genetics Center Selects Olink® Explore HT for Landmark Proteomics Study of 200,000 Patient Samples
Large-scale study aims to create comprehensive map of the human proteome to monitor changes reflecting human health and disease UPPSALA, Sweden, June 12, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced that the Regeneron Genetics Center® (RGC™) has selected the Olink Explore HT proteomics platform for a large-scale proteomics investigation involving nearly 200,000 patient samples from the Geisinger Health Study that aims to unlock new insights into the dynamic biology and mechanisms of human disease. The Geisinger Health Study, characterized by deep phenotyping data, offers a unique opportunity to monitor proteomic changes at scale. RGC's established infrastructure is designed to manage large-scale projects and is built for the efficient execution of this ambitious endeavor. RGC's selection of Olink Explore HT follows the platform's selection for use in the UK Biobank Pharma Proteomics Project (UKB-PPP), the world's largest human proteomics study. The Geisinger Health Study aims to validate genetic hypotheses, solidify drug targets identified by RGC's world-class genomic sequencing operation, and discover novel disease biomarkers to improve drug development efficiencies. Olink Explore HT was chosen for its unparalleled scalability, high throughput, and superior specificity, all of which are essential for processing such a vast number of samples. "We are thrilled to partner with RGC on this groundbreaking project," said Carl Raimond, president, proteomic sciences, Thermo Fisher Scientific. "The selection of Olink Explore HT underscores its ability to deliver robust and reliable data at scale. This important work will accelerate the pace of biomarker discovery and contribute significantly to the advancement of precision medicine." RGC is a cutting-edge research organization focused on uncovering genetic and proteomic insights, ensuring superb data stewardship, and ultimately driving scientific advancements in preventing and treating human disease. The integration of Olink Explore HT into their workflow signifies another major step forward in their commitment to leveraging multi-omics data for improved outcomes. "The Olink Explore HT platform has proven to be an invaluable tool in our pursuit of deeper biological understanding," stated John Overton, Vice President at Regeneron Genetics Center. "Its scalability and specificity are essential for handling the complexities of a project of this size. We believe this ambitious endeavor will yield transformative insights that will drive innovation in scientific discoveries." The comprehensive mapping of protein levels across such a large population of patient samples represents a significant milestone in the field of proteomics, paving the way for future studies to advance our understanding of human health and disease. Learn more about Olink Explore HT. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit View source version on Contacts Media Contact: Michael B. Gonzales, PhDThermo Fisher ScientificE-mail: Sign in to access your portfolio
Business Wire
12-06-2025
- Health
- Business Wire
Regeneron Genetics Center Selects Olink ® Explore HT for Landmark Proteomics Study of 200,000 Patient Samples
UPPSALA, Sweden--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced that the Regeneron Genetics Center ® (RGC™) has selected the Olink Explore HT proteomics platform for a large-scale proteomics investigation involving nearly 200,000 patient samples from the Geisinger Health Study that aims to unlock new insights into the dynamic biology and mechanisms of human disease. Regeneron Genetics Center selects the Olink Explore HT proteomics platform for a large-scale proteomics investigation that aims to unlock new insights into the dynamic biology and mechanisms of human disease. Share The Geisinger Health Study, characterized by deep phenotyping data, offers a unique opportunity to monitor proteomic changes at scale. RGC's established infrastructure is designed to manage large-scale projects and is built for the efficient execution of this ambitious endeavor. RGC's selection of Olink Explore HT follows the platform's selection for use in the UK Biobank Pharma Proteomics Project (UKB-PPP), the world's largest human proteomics study. The Geisinger Health Study aims to validate genetic hypotheses, solidify drug targets identified by RGC's world-class genomic sequencing operation, and discover novel disease biomarkers to improve drug development efficiencies. Olink Explore HT was chosen for its unparalleled scalability, high throughput, and superior specificity, all of which are essential for processing such a vast number of samples. "We are thrilled to partner with RGC on this groundbreaking project,' said Carl Raimond, president, proteomic sciences, Thermo Fisher Scientific. 'The selection of Olink Explore HT underscores its ability to deliver robust and reliable data at scale. This important work will accelerate the pace of biomarker discovery and contribute significantly to the advancement of precision medicine." RGC is a cutting-edge research organization focused on uncovering genetic and proteomic insights, ensuring superb data stewardship, and ultimately driving scientific advancements in preventing and treating human disease. The integration of Olink Explore HT into their workflow signifies another major step forward in their commitment to leveraging multi-omics data for improved outcomes. 'The Olink Explore HT platform has proven to be an invaluable tool in our pursuit of deeper biological understanding,' stated John Overton, Vice President at Regeneron Genetics Center. 'Its scalability and specificity are essential for handling the complexities of a project of this size. We believe this ambitious endeavor will yield transformative insights that will drive innovation in scientific discoveries.' The comprehensive mapping of protein levels across such a large population of patient samples represents a significant milestone in the field of proteomics, paving the way for future studies to advance our understanding of human health and disease. Learn more about Olink Explore HT. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit
